[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359589-105":59,"doc-detail-359589-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-the-novel-immune-checkpoint-klrg1-is-markedly-therapeutic-against-cancer-through-multiple-lymphocyte-subsets","Targeting the Novel Immune Checkpoint KLRG1 is Markedly Therapeutic Against Cancer Through Multiple Lymphocyte Subsets","","Checkpoint blockade offers clinical benefit across many cancers, yet immune-infiltrated patients often fail to respond or develop resistance. This study investigates how the inhibitory receptor KLRG1 limits antitumor immunity and evaluates KLRG1 as a therapeutic target for patients refractory to first-generation checkpoint inhibitors. Using murine models and patient tumor analyses, KLRG1 expression is linked to anti-PD-1 resistance, and KLRG1-cadherin pathway blockade reduces tumor progression in vivo.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-the-novel-immune-checkpoint-klrg1-is-markedly-therapeutic-against-cancer-through-multiple-lymphocyte-subsets/359589/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-the-novel-immune-checkpoint-klrg1-is-markedly-therapeutic-against-cancer-through-multiple-lymphocyte-subsets/359589.png","ImageObject",300,407,{"name":92,"@type":93},"Sophia Brooks","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does this study address in cancer immunotherapy?","Question",{"text":112,"@type":113},"Checkpoint therapies can benefit many patients, but immune-infiltrated tumors may remain non-responsive or become resistant. The study focuses on inhibitory pathways that could limit treatment efficacy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was KLRG1 evaluated in this research?",{"text":117,"@type":113},"Murine models were used to monitor KLRG1 after checkpoint therapy, including KLRG1 knockout and tumor N-cadherin deletion. A humanized KLRG1 knock-in model and a novel anti-human KLRG1 monoclonal antibody were tested in vitro and in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding KLRG1 and outcomes?",{"text":121,"@type":113},"KLRG1 was upregulated on murine CD8+ T cells after therapy, and high KLRG1 correlated with anti-PD-1 resistance in melanoma patients. Blocking KLRG1 signaling reduced tumor growth and improved control, including via CD8+ T cells, NK cells, and γδ T cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359589,1790194560,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Open access Original research  \nTo cite: Jones TA, Shapiro JW, Sinicrope S, et al. Targeting the novel immune checkpoint KLRG1 is markedly therapeutic against cancer through multiple lymphocyte  \nsubsets. Journal for ImmunoTherapy of Cancer 2026;14:e013869 . doi:10 . 1136/ jitc-2025-013869  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-013869](jitc-2025-013869)) .  \nAccepted 20 March 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Pathology, The University of Chicago, Chicago, Illinois, USA 2Center for Research Informatics, The University of Chicago, Chicago, Illinois, USA 3Pyxis Oncology Inc, Cambridge, Massachusetts, USA 4Department of Medicine and the Ben May Department of Cancer Research, The University of Chicago, Chicago, Illinois, USA  \nCorrespondence to  \nDr Thomas Gajewski;  \n[tgajewsk@bsd.uchicago.edu](tgajewsk@bsd.uchicago.edu)  \nTargeting the novel immune checkpoint KLRG1 is markedly therapeutic against cancer through multiple lymphocyte subsets  \nTyler Andrew Jones  ,1 Jason W Shapiro,2 Stephen Sinicrope,1 Shuyin Li,1  \nKei Yasuda  ,3 Matthew Iovino,3 Nicolas Severe,3 Jan Pinkas,3 Thomas Gajewski4  \nABSTRACT  \nBackground Checkpoint blockade therapies have demonstrated clinical benefit across multiple cancer types; however, many patients with immune cell infiltration remain non-responsive or develop resistance. This suggests that additional, unidentified regulatory pathways limit treatment efficacy. The purpose of this study was to investigate the role of the inhibitory receptor KLRG1 in limiting antitumor immunity and to evaluate its potential as a therapeutic target in patients refractory to firstgeneration checkpoint inhibitors.  \nMethods The study used murine models to observe KLRG1 expression following checkpoint therapy and analyzed tumor-infiltrating T cells from patients with melanoma non-responsive to anti-programmed death-1 (PD-1) . We generated KLRG1 knockout mice and B16 melanoma N-cadherin (KLRG1 ligand) deletions to assess tumor growth. Additionally, a KLRG1 human knock-in mouse model and a novel anti-human KLRG1 monoclonal antibody (mAb) were developed and tested both in vitro and in vivo.  \nResults KLRG1 was found to be upregulated on murine CD8+T cells post-therapy, and high KLRG1 expression correlated with anti-PD-1 resistance in patients with melanoma. KLRG1 knockout mice showed significantly reduced tumor growth, a response dependent on CD8+ T cells, natural killer cells, and γδ T cells. Similarly, deleting N-cadherin in tumors slowed growth. The novel antihuman KLRG1 mAb enhanced human T-cell activation in vitro and significantly reduced tumor progression in humanized KLRG1 mice.  \nConclusions Our findings demonstrate KLRG1 as a critical negative regulator of antitumor immunity and support KLRG1-cadherin blockade as a promising strategy for improving immunotherapy outcomes.  \nINTRODUCTION  \nAntibodies targeting programmed death-1 (PD-1) and cytotoxic T lymphocyteassociated molecule-4 (CTLA-4) have provided major clinical benefit for a variety of cancers.1 2 Patients who exhibit a T cellinflamed phenotype but fail to respond to current checkpoint blockade therapy likely have other immune-regulatory pathways that  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ Immune checkpoint blockades (eg, α-programmed death-1 (PD-1) and α-cytotoxic T lymphocyteassociated molecule-4 (CTLA-4)) are effective in many cancers, but often patients with immune cellinfiltrated tumors either do not respond or eventually become refractory, suggesting that additional regulatory pathways limit treatment efficacy. While KLRG1 is recognized as a marker of senescent/terminally differentiated T and natural killer (NK) cells, its role as a functional, druggable che","cbCaipi8K6sv1JFf","https://ap.wps.com/l/cbCaipi8K6sv1JFf","pdf",2861161,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Context and rationale\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What problem does this study address in cancer immunotherapy?\",\"answer\":\"Checkpoint therapies can benefit many patients, but immune-infiltrated tumors may remain non-responsive or become resistant. The study focuses on inhibitory pathways that could limit treatment efficacy.\"},{\"question\":\"How was KLRG1 evaluated in this research?\",\"answer\":\"Murine models were used to monitor KLRG1 after checkpoint therapy, including KLRG1 knockout and tumor N-cadherin deletion. A humanized KLRG1 knock-in model and a novel anti-human KLRG1 monoclonal antibody were tested in vitro and in vivo.\"},{\"question\":\"What were the main findings regarding KLRG1 and outcomes?\",\"answer\":\"KLRG1 was upregulated on murine CD8+ T cells after therapy, and high KLRG1 correlated with anti-PD-1 resistance in melanoma patients. Blocking KLRG1 signaling reduced tumor growth and improved control, including via CD8+ T cells, NK cells, and γδ T cells.\"}]","Targeting the Novel Immune Checkpoint KLRG1 is Markedly Therapeutic Against Cancer Through Multiple Lymphocyte Subsets | PDF",1790137231,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d162a29b1bae75eab3f5b0f51dd6bce.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e36dc8ee7457f8bbe7c9a4c8764fe91d.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f859d65fedd119efc18b62920a700079.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4294039ca22dbaf45922f0811bda1695.webp",980,1306]